干扰素诱导蛋白-10水平对接受DAAs治疗慢性丙型肝炎患者持续病毒学反应的影响

摘要/Abstract

摘要： 目的探讨干扰素诱导蛋白-10(IP-10)水平对接受直接作用抗病毒药物(DAAs)治疗慢性丙型肝炎(CHC)患者持续病毒学反应(SVR)的影响。方法回顾性分析2020年5月—2022年5月空军军医大学第一附属医院西京医院收治的60例CHC患者的临床资料,根据治疗方案不同将其分为聚乙二醇干扰素(Peg IFN)联合利巴韦林(RBV)(PR方案)组(n=20)和DAAs组(n=40),另选取10例健康体检者作为对照组。比较3组一般资料和实验室检查,探讨治疗期间CHC患者IP-10水平变化,分析IP-10水平对接受DAAs治疗CHC患者SVR的影响。结果 CHC患者的血清丙氨酸氨基转移酶(ALT)、IP-10水平及肝IP-10 mRNA、肝IP-10蛋白水平分别为[(70.8±4.7)U/L、(427.5±15.4)pg/mL、(2.0±0.4)、(2.7±0.5)],均高于对照组[(21.5±6.0)U/L、(135.1±33.5)pg/mL、1、1,P<0.05]。接受DAAs治疗期间,CHC患者的血清IP-10水平逐渐下降,且SVR患者的血清变化更为明显。多因素logistic回归分析结果显示,血清IP-10水平低于450 pg/mL、治疗12周后下降程度大于30%是预测接受DAAs治疗CHC患者SVR的独立因素(OR=5.333、5.485,P<0.05)。结论 IP-10能够干扰病毒复制,接受DAAs治疗期间CHC患者血清IP-10水平动态下降可用来预测SVR。

关键词: 慢性丙型肝炎, 持续病毒学反应, 干扰素诱导蛋白-10, 直接作用抗病毒药物

Abstract: Objective To investigate the impact of interferon-inducible protein-10 (IP-10) levels on sustained virological response (SVR) in patients with chronic hepatitis C (CHC) undergoing treatment with direct-acting antivirals (DAAs). Methods A retrospective analysis was conducted on the clinical data of 60 CHC patients admitted to Xijing Hospital, First Affiliated Hospital of Air Force Military Medical University, between May 2020 and May 2022. The patients were divided into two groups based on their treatment regimens: the peginterferon (Peg IFN) plus ribavirin (RBV) group (PR scheme, n=20) and DAAs group (n=40). An additional 10 healthy individuals were selected as the control group. The study compared the general characteristics and laboratory tests across the three groups, examined changes in IP-10 levels in CHC patients during treatment, and analyzed the impact of IP-10 level on SVR in CHC patients receiving DAAs. Results The serum alanine aminotransferase (ALT) and IP-10 levels, as well as liver IP-10 mRNA and protein levels, were significantly higher in CHC patients [(70.8 ± 4.7) U/L, (427.5 ± 15.4) pg/mL, (2.0 ± 0.4), and (2.7 ± 0.5), respectively], compared to the control group [(21.5 ± 6.0) U/L, (135.1 ± 33.5) pg/mL, 1,1[1], P<0.05]. During treatment with DAAs, the serum IP-10 levels in CHC patients gradually decreased, with more pronounced reductiosn observed in patients who achieved SVR . Multivariate logistic regression analysis identified a serum IP-10 level below 450 pg/mL and a reduction of more than 30% after 12 weeks of treatment as independent predictors of SVR in CHC patients treated with DAAs (OR=5.333, 5.485, P<0.05). Conclusion IP-10 can interfere with virus replication, and the dynamic decrease in serum IP-10 levels in CHC patients during DAAs treatment can serve as a predictor of SVR.

Key words: Chronic hepatitis C, Continuous virological response, Interferon inducible protein-10, Direct acting antivirals

陈小玉, 贾桂, 孟琴, 杨春梅. 干扰素诱导蛋白-10水平对接受DAAs治疗慢性丙型肝炎患者持续病毒学反应的影响[J]. 肝脏, 2024, 29(9): 1109-1112.

CHEN Xiao-yu, JIA Gui, MENG Qin, YANG Chun-mei. Impact of interferon-inducible protein-10 levels on sustained virological response in chronic hepatitis C patients treated with direct-acting antivirals[J]. Chinese Hepatolgy, 2024, 29(9): 1109-1112.

/ 推荐

参考文献

[1] Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, 2019, 393(10179): 1453-1464.
[2] 李宁侠, 唐招平, 狄友华. IL-28B血清水平和遗传变异与慢性丙型肝炎患者病毒基因型及疾病进展相关性分析. 中华医院感染学杂志, 2017, 27(9): 1924-1928.
[3] Abdelsameea E, Alsebaey A, Abdel-Samiee M, et al. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Rev Anti-infe, 2021, 19(8): 1053-1059.
[4] Adinolfi L E, Petta S, Fracanzani A L, et al. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: a prospective study. Diabetes Obes Metab, 2020, 22(12): 2408-2416.
[5] 刘娜, 张长庚, 李伟, 等. 趋化因子γ干扰素诱导蛋白-10和巨噬细胞炎性蛋白-3a在肝癌患者外周血中的表达及诊断价值. 实用医学杂志, 2019, 35(16): 2641-2644.
[6] 王美霞, 牛俊奇. AASLD基因1型慢性丙型肝炎病毒感染治疗指南2011年更新版. 临床肝胆病杂志, 2011, 27(12): 1245-1254.
[7] Gaballah A, Naga I S, Zaghloul M S, et al. Changes in the co-expressions of interleukin 29 (IL-29), IFN-inducible protein 10 (IP-10) and monokine induced by IFNγ (MIG) genes in chronic hepatitis c egyptian patients untreated and treated with DAAs. Acta Virol, 2021, 65(2): 141-148.
[8] Talaat R M, Elsharnoby S, Abdelkhalek M S, et al. The Impact of Interferon-γ (IFN-γ) and IFN-γ-Inducible Protein 10 (IP-10) Genes’ Polymorphism on Risk of Hepatitis C Virus-Related Liver Cirrhosis. Immunol Invest, 2022, 51(3): 688-704.
[9] Wang C C, Tseng K C, Tzeng I S, et al. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. J Formos Med Assoc, 2021, 120(3): 965-973.
[10] El-Nahaas S M, Rady N H, Malek S, et al. Changes in serum interferon-γ-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents. Eur J Gastroen Hepat, 2021, 33(1): 335-340.
[11] ELmishad M Y, Gouda A A, Nada A S E, et al. Study of Interferon-γ-Inducible Protein 10 (IP 10) Level as a Diagnostic and Prognostic Marker in Patients on Sofosbuvir and Daclatasvir as Antiviral Therapy of Chronic Hepatitis C. The Egyptian Journal of Hospital Medicine, 2019, 77(4): 5434-5441.
[12] Xu X W, Wu X X, Chen K D, et al. Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study. Medicine, 2018, 97(38):e12403.
[13] 黄少军, 程瑾, 汪晶晶, 等. 乙型肝炎病毒相关慢加急性(亚急性)肝功能衰竭患者外周血单个核细胞中干扰素诱导蛋白-10的表达及其对预后的判断价值. 中华传染病杂志, 2018, 36(6): 340-344.
[14] Masalova O V, Lesnova E I, Klimova R R, et al. Mesenchymal Stem Cells Can Both Enhance and Inhibit the Cellular Response to DNA Immunization by Genes of Nonstructural Proteins of the Hepatitis C Virus. Int J Mol Sci, 2021, 22(15): 8121.
[15] 魏霞, 杨莉. 泛基因型直接抗病毒药物治疗慢性丙型肝炎的成本-效用分析. 中国药房, 2021, 32(8): 979-985.
[16] Shiha G, Mousa N, Soliman R, et al. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. J Viral Hepatitis, 2020, 27(7): 671-679.
[17] Fan R, Yin X, Hou J. Reply to:“External validation of aMAP risk score in patients with chronic hepatitis C genotype 4 and cirrhosis who achieved SVR following DAAs”. J Hepatol, 2021, 74(4): 996-997.
[18] Galati G, Muley M, Viganò M, et al. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opin Drug Saf, 2019, 18(7): 603-610.